Canada Markets closed

BELLUS Health Inc. (BLU.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
15.11+0.58 (+3.99%)
At close: 04:00PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • S
    Spark
    Why is this going down?
  • D
    DipBuy$$$
    I’m so happy, I got it for $4.09. Now it’s time to get some profit 🤑
  • M
    MrPunchy
    this little gem is going to shine let's go
  • n
    nkov
    Hi, am I the only long who cares???
  • P
    Pete
    Wow !! All this without any news
  • D
    Duane
    You've got a Whale 🐋 on the Hook 🪝
  • S
    Sam
    What’s the news
  • j
    jirawut
    These go be like $SBFM Also canada stock.
  • M
    M
    The 3rd high close in the past few months. Once we close above 12.55; I charterdly see it in free float specially after the FDA nod to start P3.
  • J
    Jeff
    Moon
  • n
    nkov
    Any clues?
  • R
    Ram
    Huge bull call.. upgrade with target to $12... 400% upside that is the reason stock is moving up,,,

    https://seekingalpha.com/news/3637474-huge-bull-call-on-bellus-health-from-evercore-impliesplus-400-upside
    Stock Picks, Stock Market Investing
    seekingalpha.com
  • J
    J
    People always take profit when there is an announcement of Phase trials where the instant gratification is not there... BLU will continue to steadily climb. Those cashing in will regret it.
  • B
    Bildo
    From the Bellus web site: "second half of 2020"

    BELLUS Health believes BLU-5937 may be a viable treatment option for patients with chronic pruritus associated with atopic dermatitis. The Company has conducted preclinical studies of BLU-5937 in pruritus, and expects to initiate a Phase 2 trial to assess the efficacy, safety, and tolerability of BLU-5937 versus placebo in approximately 100 patients suffering from chronic pruritus associated with mild to moderate atopic dermatitis in the second half of 2020.
  • V
    Victor
    Spoke with Danny Matthews yesterday about upcoming events etc. Bio conference in 5 weeks, earnings August 13th (of course as a clinical stage biotech, I expect minimal revenue but more interested in updates and announcements). Stock is trading at only 2 times cash and extremely undervalued. Executives loading up is a major vote of confidence as well as some tunes that have been increasing their positions.
  • P
    Pellegrino
    BLU broke that $4.46 resistance. It's in gap fill land now. We made it guys, it's a smooth ride from now on. Holding since last summer with an entry at $2.10. Long term investing wins again for me.
  • t
    theofficialslimebros
    Been holding for 4 months and am just now seeing green. Doesn't make any sense to sell now when the show has just began!
  • I
    Isiah
    I have mixed feelings about BLU. Cash situation is good: $98.3M, expected to be enough to fund operations through 2022. On 2/18, RBC Capital analyst Gregory Renza gave BLU an Outperform rating and an $8 TP. BLU-5937 would be the only approved therapy for chronic cough patients but BLU’s Phase 2 trial didn’t meet its endpoint in July and BLU’s price fell from $12 to $2 in a matter of days. There’s a lot of risk here.